106 results
8-K
EX-99.1
FGEN
FibroGen Inc
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
by the China Health Authority. FibroGen recently expanded its research and development portfolio to include antibody-drug conjugate (ADC) and immuno … revenue, net
Total revenue
Operating costs and expenses:
Cost of goods sold
Research and development
Selling, general and administrative
Restructuring
8-K
EX-99.1
FGEN
FibroGen Inc
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
accepted by the China Health Authority. FibroGen recently expanded its research and development portfolio to include product candidates in oncology … and other revenue
Product revenue, net
Drug product revenue, net
Total revenue
Operating costs and expenses:
Cost of goods sold
Research
8-K
EX-99.1
g05j1
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
EX-99.1
j2z5xauv 8p8u83ths
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
fpxdm6zp69n
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
EX-99.1
cz352gfz1yquq8yzhwv8
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
950qefsnlngpafmu
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
EX-99.1
xwb3 kq1dv05mshgk4dm
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
8-K
EX-99.1
lexe4u eh9nvr8
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm